Novo Nordisk reported results Monday for its trial to determine whether the active ingredient in Ozempic and Wegovy could slow the progression of Alzheimer's. Sergei Gapon / AFP / Getty Images Close Key Takeaways Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial. The company had been looking to determine whether semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, could also slow the cognitive decline associated wit ...

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.BIIB is reaching significant price levels. Watch the momentum hereThe trials did not confirm the superiority of semaglutide versus placebo in the reduction of progression of Alzheimer's disease, as measured by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score ...

Shares of Danish pharma major Novo Nordisk's plummeted a record 12.4% on 24 November — it's lowest since July 2021, after the company's popular weight-loss pill Ozempic failed trials for Alzheimer's treatment, Bloomberg reported.Novo Nordisk has discontinued its planned one-year extension for the pair of studies that were testing the drug's effectiveness in slowing the progression of Alzheimer's disease, it added.The two trials, with 3,500 participants with mild Alzheimer’s disease, had a 75% probability of ...

Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.The company had been testing whether a key ingredient in the drugs could slow progression of the brain disorder. Novo Nordisk, which began the trials two years ago, had always treated the study as an outside bet but one which had the potential to land big rewards, if successful, as earnings from its core diabetes ...

Core Insights - Shares of Novo Nordisk fell by as much as 11% following the announcement that a trial for Alzheimer's disease did not meet its primary objective [1] Group 1: Company Performance - The trial evaluated the effectiveness of semaglutide, the active ingredient in Novo's successful diabetes and weight loss medications Ozempic and Wegovy, in slowing the progression of Alzheimer's disease [1]

Core Insights - Novo Nordisk announced top-line results from the phase 3 evoke and evoke+ trials for oral semaglutide in early-stage symptomatic Alzheimer's disease, involving 3,808 adults [1][2] - The trials did not show superiority of semaglutide over placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers [2][4] - The decision to explore semaglutide for Alzheimer's was based on real-world evidence and previous studies, although the likelihood of success was considered low [4] Study Details - The evoke and evoke+ trials were randomized, double-blind, and placebo-controlled, focusing on patients aged 55-85 with mild cognitive impairment or mild dementia due to Alzheimer's [3][7] - Semaglutide was administered at a dose of 14 mg once daily, with a total of 1,855 and 1,953 participants randomized in the two trials respectively [7] - The primary measure of efficacy was the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline to week 104 [6][7] Safety and Tolerability - Semaglutide demonstrated a safe and well-tolerated profile consistent with previous trials, with over 37 million patient-years of exposure across various populations [3][4] - The one-year extension period of the trials will be discontinued due to the lack of efficacy observed [4] Future Presentations - Topline results will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025, with full results to follow at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026 [4]

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clini ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50.Check out the current price of INM stock here. The stock closed Wednesday's regular session at $1.23, down 15.75%, according to Benzinga Pro data.Large Study MilestoneThe Vancouver-based pharmaceutical company announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer’s disease candidate INM-901, according to a Tuesday press release.This was the first precl ...

Core Insights - BioArctic AB's partner Eisai will present new findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, focusing on long-term treatment benefits, safety, and subcutaneous administration [1][5][9] Presentation Highlights - Key presentations will include data on long-term treatment effects and estimated time savings over 10 years, as well as safety and benefits of subcutaneous dosing for initiation [1][5] - Real-world clinical practice insights will be shared, including findings from the US ALZ-NET registry [1][5] Poster Presentations - A poster session will cover various studies, including baseline characteristics and safety findings from the ALZ-NET registry [3] - Additional topics include enrollment patterns in preclinical trials, stability and improvement in early Alzheimer's disease, and patient acceptability of the autoinjector for subcutaneous delivery [4] Continued Treatment Analysis - New analyses will be presented on the benefits of continued lecanemab therapy and estimated time savings based on Phase 3 clinical data [5][7] - A late-breaking symposium will discuss the potential benefits of subcutaneous initiation dosing and related pharmacokinetic findings [5] Mechanism and Clinical Outcomes - Presentations will review the effects of lecanemab on soluble amyloid-beta protofibrils and clinical outcomes from subcutaneous administration [6][7] - A societal cost comparison between subcutaneous and intravenous lecanemab will also be discussed [7] Collaboration and Development - Lecanemab is a result of a long-term collaboration between BioArctic and Eisai, with BioArctic holding commercialization rights in the Nordic region [7][11] - The drug is approved in 51 countries and under review in 9, with a focus on subcutaneous dosing in the U.S. [9][11]

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901November 18, 2025 7:30 AM EST | Source: InMed PharmaceuticalsData demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" ...